INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 79 filers reported holding INFINITY PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $12,419 | -82.9% | 59,000 | -87.0% | 0.00% | – |
| Q1 2023 | $72,527 | +132.9% | 453,296 | +708.0% | 0.00% | – |
| Q4 2022 | $31,136 | -60.1% | 56,100 | -14.2% | 0.00% | – |
| Q3 2022 | $78,000 | -74.9% | 65,400 | -86.7% | 0.00% | – |
| Q2 2022 | $311,000 | +70.9% | 490,701 | +206.5% | 0.00% | – |
| Q1 2022 | $182,000 | -73.0% | 160,105 | -46.5% | 0.00% | – |
| Q4 2021 | $673,000 | -49.7% | 299,504 | -23.5% | 0.00% | – |
| Q3 2021 | $1,339,000 | +91.8% | 391,267 | +67.5% | 0.00% | – |
| Q2 2021 | $698,000 | -60.0% | 233,647 | -56.8% | 0.00% | – |
| Q1 2021 | $1,745,000 | +2626.6% | 540,312 | +1689.1% | 0.00% | – |
| Q4 2020 | $64,000 | +357.1% | 30,200 | +86.8% | 0.00% | – |
| Q1 2020 | $14,000 | -68.2% | 16,165 | -64.4% | 0.00% | – |
| Q4 2019 | $44,000 | +57.1% | 45,384 | +65.4% | 0.00% | – |
| Q3 2019 | $28,000 | -48.1% | 27,434 | -8.5% | 0.00% | – |
| Q2 2019 | $54,000 | -59.4% | 29,991 | -57.8% | 0.00% | – |
| Q1 2019 | $133,000 | +3.9% | 70,985 | -34.3% | 0.00% | – |
| Q4 2018 | $128,000 | -39.9% | 108,087 | +37.2% | 0.00% | – |
| Q3 2018 | $213,000 | +55.5% | 78,778 | +9.6% | 0.00% | – |
| Q2 2018 | $137,000 | +18.1% | 71,900 | +30.2% | 0.00% | – |
| Q1 2018 | $116,000 | +96.6% | 55,211 | +89.3% | 0.00% | – |
| Q4 2017 | $59,000 | +321.4% | 29,171 | +175.5% | 0.00% | – |
| Q3 2017 | $14,000 | -48.1% | 10,590 | -38.4% | 0.00% | – |
| Q2 2017 | $27,000 | -90.3% | 17,204 | -80.1% | 0.00% | – |
| Q1 2017 | $279,000 | +548.8% | 86,522 | +169.2% | 0.00% | – |
| Q4 2016 | $43,000 | 0.0% | 32,144 | +18.0% | 0.00% | – |
| Q3 2016 | $43,000 | -87.0% | 27,251 | -30.3% | 0.00% | – |
| Q3 2015 | $330,000 | -95.6% | 39,100 | -92.6% | 0.00% | -100.0% |
| Q1 2015 | $7,428,000 | -1.9% | 531,294 | +18.5% | 0.01% | 0.0% |
| Q4 2014 | $7,571,000 | +1673.1% | 448,247 | +1307.3% | 0.01% | – |
| Q3 2014 | $427,000 | -3.2% | 31,852 | -0.3% | 0.00% | -100.0% |
| Q4 2013 | $441,000 | -88.7% | 31,941 | -85.7% | 0.00% | -83.3% |
| Q3 2013 | $3,888,000 | +257.7% | 222,801 | +233.0% | 0.01% | +200.0% |
| Q2 2013 | $1,087,000 | – | 66,914 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,354,963 | $38,132,000 | 1.80% |
| Orbimed Advisors | 4,520,800 | $73,201,000 | 1.55% |
| QVT Financial LP | 1,326,610 | $21,480,000 | 1.44% |
| BB BIOTECH AG | 1,089,828 | $17,646,000 | 1.27% |
| Meditor Group Ltd | 250,000 | $4,048,000 | 0.55% |
| Perimeter Capital Partners, LLC | 159,915 | $2,589,000 | 0.50% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 156,808 | $2,539,000 | 0.43% |
| Broadfin Capital, LLC | 117,172 | $1,897,000 | 0.37% |
| OXFORD ASSET MANAGEMENT LLP | 811,331 | $13,184,000 | 0.36% |
| Baker Brothers Advisors | 1,016,433 | $16,458,000 | 0.33% |